BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Analysts at Wedbush increased their Q4 2021 earnings estimates for shares of BioMarin Pharmaceutical in a research report issued to clients and investors on Sunday, November 21st. Wedbush analyst L. Moussatos now anticipates that the biotechnology company will earn ($0.02) per share for the quarter, up from their previous forecast of ($0.03). Wedbush currently has a “Outperform” rating and a $152.00 target price on the stock.
A number of other research analysts have also recently issued reports on BMRN. Zacks Investment Research cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating and set a $81.00 price target for the company. in a report on Tuesday, August 3rd. SVB Leerink boosted their price objective on BioMarin Pharmaceutical from $112.00 to $115.00 and gave the company an “outperform” rating in a research report on Monday. Robert W. Baird boosted their price objective on BioMarin Pharmaceutical from $101.00 to $112.00 and gave the company an “outperform” rating in a research report on Tuesday. Jefferies Financial Group assumed coverage on BioMarin Pharmaceutical in a research report on Thursday, July 29th. They set a “buy” rating and a $112.00 price target for the company. Finally, JPMorgan Chase & Co. upped their price objective on BioMarin Pharmaceutical from $129.00 to $135.00 and gave the stock an “overweight” rating in a research note on Monday. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $107.53.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Tuesday, October 26th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.05. The business had revenue of $408.74 million for the quarter, compared to the consensus estimate of $435.29 million. BioMarin Pharmaceutical had a net margin of 0.86% and a return on equity of 2.02%. BioMarin Pharmaceutical’s quarterly revenue was down 14.3% on a year-over-year basis. During the same quarter last year, the company posted $0.29 earnings per share.
Large investors have recently bought and sold shares of the business. Voloridge Investment Management LLC purchased a new position in shares of BioMarin Pharmaceutical during the first quarter valued at approximately $4,042,000. Canada Pension Plan Investment Board boosted its holdings in BioMarin Pharmaceutical by 242.4% in the first quarter. Canada Pension Plan Investment Board now owns 208,807 shares of the biotechnology company’s stock valued at $15,767,000 after purchasing an additional 147,827 shares during the last quarter. Paloma Partners Management Co boosted its holdings in BioMarin Pharmaceutical by 105.9% in the first quarter. Paloma Partners Management Co now owns 14,985 shares of the biotechnology company’s stock valued at $1,131,000 after purchasing an additional 7,707 shares during the last quarter. Axiom Investment Management LLC purchased a new stake in shares of BioMarin Pharmaceutical during the 1st quarter worth about $204,000. Finally, Teachers Retirement System of The State of Kentucky boosted its stake in shares of BioMarin Pharmaceutical by 11.6% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 253,058 shares of the biotechnology company’s stock worth $19,108,000 after acquiring an additional 26,305 shares in the last quarter. 94.28% of the stock is currently owned by institutional investors and hedge funds.
In other BioMarin Pharmaceutical news, EVP Jeffrey Robert Ajer sold 2,739 shares of the company’s stock in a transaction that occurred on Tuesday, October 26th. The stock was sold at an average price of $73.60, for a total transaction of $201,590.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.69% of the company’s stock.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.
Featured Story: Non-Fungible Token (NFT)
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.